Zoetis (NYSE:ZTS) Given New $80.00 Price Target at UBS Group

Zoetis (NYSE:ZTS) had its price target reduced by UBS Group from $85.00 to $80.00 in a research note published on Friday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other brokerages also recently commented on ZTS. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Barclays cut their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Citigroup reduced their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $115.50.

Zoetis Stock Down 6.1%

Shares of NYSE ZTS opened at $72.53 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market capitalization of $30.41 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.34 and a beta of 0.74. The stock’s fifty day simple moving average is $76.66 and its two-hundred day simple moving average is $100.75. Zoetis has a 12-month low of $71.47 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts expect that Zoetis will post 6.2 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s payout ratio is presently 35.16%.

Insider Transactions at Zoetis

In related news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. J. Stern & Co. LLP grew its holdings in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. Norges Bank purchased a new position in Zoetis in the 4th quarter worth $734,425,000. Vanguard Group Inc. raised its stake in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. BlackRock Inc. lifted its position in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. acquired a new stake in Zoetis during the 1st quarter worth about $286,660,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.